North America Intragastric Balloon Market Size, Share, and Growth Forecast 2026 - 2033

The North America intragastric balloon market size is expected to be valued at US$ 30.8 million in 2026 and projected to reach US$ 47.2 million by 2033, growing at a CAGR of 6.3% between 2026 and 2033.

Rising obesity prevalence combined with growing patient preference for minimally invasive, non-surgical weight loss interventions continues to drive steady market expansion across the region.

The Centers for Disease Control and Prevention reports that a substantial share of American adults are classified as obese, creating a large addressable population for non-surgical bariatric interventions. Meanwhile, expanding U.S. Food and Drug Administration approvals for newer balloon systems, combined with growing awareness among gastroenterologists and bariatric surgeons regarding intragastric balloon therapy as a bridge or alternative to invasive bariatric surgery, continue to reinforce sustained demand across hospitals, bariatric surgery centers, and ambulatory surgical settings throughout North America.

Drivers - Rising Obesity Prevalence and Growing Demand for Non-Surgical Weight Loss Solutions

Escalating obesity rates across the United States and Canada remain the primary driver of the North American Intragastric Balloon Market. The Centers for Disease Control and Prevention reports that more than 40% of American adults are classified as obese, creating substantial demand for effective, minimally invasive weight management interventions. Growing patient reluctance toward invasive bariatric surgical procedures, combined with rising awareness of intragastric balloon therapy as a reversible, non-surgical alternative, continues to expand the addressable patient population.

The American Society for Metabolic and Bariatric Surgery has also highlighted growing physician interest in device-based weight loss interventions for patients who do not qualify for or prefer to avoid surgical bariatric procedures. This combination of rising obesity prevalence and increasing preference for non-surgical treatment pathways sustains strong demand for intragastric balloon systems across hospitals, bariatric surgery centers, and specialty gastroenterology clinics throughout the region.

Expanding FDA Approvals and Technological Advancements in Balloon Systems

Continued regulatory approval activity from the U.S. Food and Drug Administration for next-generation intragastric balloon systems represents a second significant growth driver. Innovations such as swallowable, procedureless balloon systems and adjustable balloon technologies are expanding treatment accessibility by eliminating the need for endoscopic placement under sedation, thereby broadening the pool of eligible patients and treating physicians. Companies including Allurion Technologies, Inc. and Spatz FGIA, Inc. continue to advance next-generation balloon platforms designed to improve patient tolerability and enable more precise, individualized volume adjustment throughout the treatment period.

As clinical evidence supporting sustained weight loss outcomes continues to accumulate, gastroenterologists and bariatric specialists across the United States and Canada increasingly incorporate intragastric balloon therapy into comprehensive weight management protocols, reinforcing consistent demand across the region's treatment centers.

Restraints - Limited Insurance Reimbursement Coverage for Intragastric Balloon Procedures

Limited insurance reimbursement coverage for intragastric balloon procedures continues to restrain broader market adoption across the United States and Canada. Unlike many surgical bariatric interventions, intragastric balloon placement is frequently classified as an elective, out-of-pocket procedure by private insurers and government health programs, creating a significant financial barrier for price-sensitive patients.

This lack of standardized reimbursement policy discourages a share of eligible patients from pursuing balloon-based treatment, particularly among lower-income populations who may otherwise benefit clinically from non-surgical weight loss intervention, moderating overall market growth despite rising obesity-related demand across the region.

Device-Related Adverse Events and Regulatory Safety Communications

Reported adverse events associated with certain intragastric balloon systems, including gastric hyperinflation and rare cases of spontaneous deflation, continue to constrain market growth. The U.S. Food and Drug Administration has previously issued safety communications regarding specific balloon systems following reports of serious complications, prompting heightened physician caution and, in some cases, market withdrawal of affected products. This safety scrutiny has contributed to more conservative patient selection criteria and extended physician training requirements, which collectively slow the pace of broader clinical adoption despite the therapy's demonstrated efficacy for appropriately selected patients across hospitals and bariatric surgery centers.

Opportunities -Expanding Adoption of Swallowable, Procedureless Balloon Technologies

Swallowable balloon systems represent a substantial growth opportunity for market participants, as procedureless placement eliminates the need for endoscopy and sedation, significantly broadening the addressable patient population and reducing procedural costs. Allurion Technologies, Inc. continues to expand commercial availability of its swallowable balloon platform, supported by growing physician training programs across the United States and Canada. This technology particularly appeals to specialty gastroenterology clinics and ambulatory surgical centers seeking to offer efficient, lower-overhead weight management services without dedicated endoscopy suites.

As patient preference increasingly shifts toward convenient, office-based treatment options, companies investing in procedureless balloon technology and remote patient monitoring capabilities are well positioned to capture rising demand from both clinicians and patients seeking accessible non-surgical weight loss solutions through the forecast period.

Rising Integration of Adjustable Balloon Systems Within Personalized Weight Management Protocols

Growing clinical interest in adjustable balloon technology presents a significant opportunity for companies offering customizable, volume-adjustable systems. Spatz FGIA, Inc. continues to expand adoption of its adjustable balloon platform, which allows physicians to modify balloon volume during the treatment period to optimize patient tolerability and weight loss outcomes. This flexibility addresses a key clinical limitation of fixed-volume balloon systems, particularly for patients experiencing early intolerance symptoms.

Growing collaboration between bariatric surgery centers and specialty gastroenterology clinics on individualized treatment protocols, combined with expanding physician training in adjustable balloon placement and management techniques, is expected to accelerate adoption. Companies investing in extended-duration adjustable balloon platforms are positioned to capture meaningful incremental revenue as personalized weight management approaches gain broader clinical acceptance across North America.

Product Analysis

Single Balloon systems remained the leading product segment, accounting for 32% of the North America intragastric balloon market share in 2026. This dominance reflects the segment's established clinical track record, straightforward endoscopic placement procedure, and broad physician familiarity compared to newer dual or adjustable balloon designs.

Single balloon systems remain the standard treatment choice across hospitals and bariatric surgery centers, supported by extensive long-term clinical data demonstrating consistent weight loss outcomes. Their widespread availability and relatively lower cost compared to advanced adjustable systems further reinforce sustained demand among both physicians and patients. Meanwhile, Dual Balloon systems are projected to be the fastest-growing product segment through 2033, driven by rising clinical interest in dual-balloon designs that distribute gastric volume displacement more evenly, potentially improving patient tolerability and reducing early removal rates compared to single balloon alternatives.

End-user Analysis

Bariatric surgery centers represented the leading end-user segment, accounting for approximately 38% of the North America intragastric balloon market share in 2026. Specialized bariatric centers maintain the largest share due to their concentrated clinical expertise in weight management interventions, established patient referral networks, and comprehensive pre- and post-procedure support programs tailored to intragastric balloon patients.

The American Society for Metabolic and Bariatric Surgery has highlighted the growing role of accredited bariatric centers in delivering coordinated, multidisciplinary weight management care across the United States and Canada. Meanwhile, Ambulatory Surgical Centers (ASCs) are projected to be the fastest-growing end-user segment through 2033, as the minimally invasive, same-day nature of balloon placement procedures increasingly shifts toward lower-cost outpatient settings, supported by expanding ASC accreditation and growing physician preference for efficient, cost-effective procedural environments.

North America Intragastric Balloon Market Trends and Insights

North America represents a mature and technologically advanced intragastric balloon market, supported by high obesity prevalence, extensive bariatric care infrastructure, and strong physician awareness of device-based weight management interventions. The United States dominates regional demand, supported by robust U.S. Food and Drug Administration approval activity and a dense network of accredited bariatric surgery centers, while Canada is emerging as a steadily growing market driven by rising obesity-related healthcare initiatives.

Growing adoption of swallowable and adjustable balloon technologies, combined with expanding ambulatory surgical center utilization, continues to shape regional demand trends across hospitals, bariatric centers, and specialty gastroenterology clinics throughout North America.

U.S. Intragastric Balloon Market Size

The United States accounts for approximately 89% of the North America Intragastric Balloon Market share in 2025, supported by the region's highest obesity prevalence, extensive bariatric surgery center infrastructure, and continuous product innovation from domestic manufacturers including Allurion Technologies, Inc. and Spatz FGIA, Inc. Ongoing U.S. Food and Drug Administration approval activity for next-generation swallowable and adjustable balloon systems, combined with growing physician training programs across gastroenterology and bariatric surgery specialties, continues to reinforce the country's dominant position within the regional market through the forecast period.

Canada Intragastric Balloon Market Size

Canada represents a steadily growing market within North America, supported by rising obesity-related healthcare initiatives and expanding physician awareness of non-surgical weight management interventions across provincial healthcare systems. Health Canada's regulatory approval of select intragastric balloon systems continues to broaden treatment accessibility for eligible patients. Growing collaboration between Canadian bariatric centers and specialty gastroenterology clinics on structured weight management protocols, combined with rising patient interest in minimally invasive alternatives to bariatric surgery, continues to support gradual market expansion across the country through 2033.

The North America intragastric balloon market remains moderately fragmented, comprising established device manufacturers alongside specialized companies focused exclusively on balloon-based weight management technology. Leading companies including Boston Scientific Corporation, Allurion Technologies, Inc., and Spatz FGIA, Inc. compete through continuous product innovation, expanded physician training programs, and strategic differentiation across single, dual, swallowable, and adjustable balloon platforms.

Companies are increasingly emphasizing procedureless placement technology, extended treatment durations, and remote patient monitoring capabilities to differentiate their offerings. Strategic partnerships with bariatric surgery centers and specialty gastroenterology clinics for coordinated patient care programs remain common, while smaller specialized manufacturers compete through niche adjustable balloon and dual-balloon innovations targeting specific patient tolerability profiles across the region.

Key Developments:

• In February 2026, Allurion Technologies received U.S. FDA premarket approval (PMA) for its Allurion Gastric Balloon System featuring the Allurion Smart Capsule, enabling its entry into the U.S. obesity-treatment market. The swallowable balloon is designed to provide weight loss without surgery, endoscopy, or anesthesia, strengthening Allurion’s position in the intragastric balloon market.